NASDAQ:EGRX Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis $1.80 +0.18 (+11.11%) As of 04/17/2025 10:44 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock About Eagle Pharmaceuticals Stock (NASDAQ:EGRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eagle Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.55▼$1.8050-Day Range$0.85▼$1.8952-Week Range$0.00▼$6.37Volume280 shsAverage Volume8,157 shsMarket Capitalization$23.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Read More… Receive EGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EGRX Stock News HeadlinesEagle Pharmaceuticals announces $69M pact to monetize Bendeka royaltiesApril 1, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesMarch 31, 2025 | markets.businessinsider.comWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsApril 18, 2025 | True Market Insiders (Ad)Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanMarch 21, 2025 | globenewswire.comEagle Pharmaceuticals to Delist from NasdaqNovember 19, 2024 | investing.comEagle Announces Update on Delisting from Nasdaq and SEC DeregistrationNovember 15, 2024 | globenewswire.comEagle Pharmaceuticals Appoints New CFO Amid Leadership ChangeNovember 12, 2024 | markets.businessinsider.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNovember 1, 2024 | finanznachrichten.deSee More Headlines EGRX Stock Analysis - Frequently Asked Questions How have EGRX shares performed this year? Eagle Pharmaceuticals' stock was trading at $0.50 on January 1st, 2025. Since then, EGRX stock has increased by 260.0% and is now trading at $1.80. View the best growth stocks for 2025 here. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) posted its quarterly earnings data on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, topping the consensus estimate of ($0.44) by $1.00. The specialty pharmaceutical company had revenue of $39.85 million for the quarter, compared to analyst estimates of $46.70 million. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eagle Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/09/2021Today4/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EGRX CIK827871 Webwww.eagleus.com Phone(201) 326-5300FaxN/AEmployees100Year Founded2007Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$257.55 million Price / Sales0.09 Cash Flow$4.50 per share Price / Cash Flow0.40 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares12,987,000Free Float9,234,000Market Cap$23.38 million OptionableNo Data Beta0.83 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:EGRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.